We recently published a list of 10 Stocks Stand Strong Amid Cautious Market Environment. In this article, we are going to ...

Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

B. Riley lowered the firm’s price target on Viking Therapeutics (VKTX) to $96 from $109 and keeps a Buy rating on the shares.

Viking Therapeutics VKTX has outperformed the market over the past 5 years by 22.07% on an annualized basis producing an ...

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price target ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Shares of Viking Therapeutics have fallen by more than half since the stock peaked early last year. Viking Therapeutics is developing a drug that might be able to outperform today's most popular ...

Investing.com - Viking Therapeutics Inc (NASDAQ: VKTX) reported fourth quarter EPS of $-0.250, $0.01 better than the analyst estimate of $-0.260. Revenue for the ...

Nearly a year ago, Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results from a clinical trial with an experimental weight loss ...

When the market closed on Feb. 5, shares of Viking Therapeutics were down about 65% from the peak they reached in 2024. Is Viking Therapeutics stock a bargain at its beaten-down price?